Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provid
'/>"/>

SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... 27, 2015  Johnson & Johnson (NYSE: JNJ ) ... (Eastern Time) on Thursday, April 23, 2015, from the State ... Investors and other interested parties may access the live ... at www.jnj.com and clicking on the webcast icon. ... be made available a few hours after the live meeting ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Inc. (Nasdaq: MYL ) CEO Heather Bresch today ... Committee at a hearing hosted by the subcommittee on Health ... Fees and Further Examination of Drug Shortages." In ... of mind in knowing that every prescription, brand or generic, ...
... Mass., Feb. 9, 2012 Syndax Pharmaceuticals, ... that scientists at Roswell Park Cancer Institute have ... inhibitor of class I histone deacetylases, has novel ... of cancer immunotherapies in models of renal and ...
Cached Medicine Technology:Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 2Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 3
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
(Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... , NEW YORK, Aug. 14 MS ... conducted by AstraZeneca, found that while most patients with asthma ... act accordingly. , , "This finding ... asthma and the necessary steps people should take to achieve ...
... ... present a technology and admissions educational session for THCA members , ... Atlanta, GA (PRWEB) August 14, 2009 ... providers, announced today that it will present a session at the Tennessee Health Care ...
... ... collision avoidance method used in uncontrolled areas, risks inherent in such situations , ... San Mateo, CA (Lexis Nexis) August 14, ... August 8th, in which nine people were killed when a small aircraft collided in midair ...
... , SACRAMENTO, Calif., Aug. 13 The ... million to the Healthy Families Program today to cover health care costs ... due to the state,s fiscal crisis. The funding, approved at a special ... 0-5 through June 2010. , , "In the current ...
... ... of Sexual Health in His New Book ,Ultimate Sexual Health & Performance, , ... Los Angeles, California (Vocus) August 13, 2009 ... his book ,Ultimate Sexual Health & Performance., Bringing over 35 years of research and ...
... , , JACKSON, Miss., Aug. 13 ... benefits for speech therapy services, The Mississippi School Boards Association and ... the new Medicaid claiming policy for the coming school year . ... by school providers, which are in fact still claimable. Specifically, ...
Cached Medicine News:Health News:Keeping Asthma Under Control 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Midair Collision over Hudson Provides Tragic Reminder that Airplanes and Helicopters Don't Mix Well, According to Aviation Law Expert 2Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Definitive Sexual Health Book Released 2Health News:Definitive Sexual Health Book Released 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3
... control is designed for monitoring human urine ... routine and stat testing and meets CLIA ... are included for most frequently tested analytes. ... chemistry analyzers including: Aeroset, AU Series, Cobas, ...
... control validates urine dipstick readings by applying ... a plastic dropper tip designed for easy ... is the addition of creatinine and microalbumin. ... qualitative results for hCG for early pregnancy ...
... quanTtest human protein standards are available in ... and 200 mg/dL and are packaged in ... ready-to-use, requiring no reconstitution or dilution and ... purified human albumin and human globulin at ...
... is a completely new concept ... use of optic technology for ... applying touch-less vibration system (Patent ... ergonomic user friendly, novel design ...
Medicine Products: